Health> Vol.6 No.2, January 2014

Antimicrobial susceptibility of strains of Enterobacteriaceae isolated from bloodstream infections using current CLSI and EUCAST breakpoints

DownloadDownload as PDF (Size:150KB) Full-Text HTML PP. 153-157   DOI: 10.4236/health.2014.62024

ABSTRACT

Understanding local susceptibility patterns is important when selecting antimicrobials for initial empirical antibiotic-therapy of bloodstream infections. Because the determination of susceptibility is dependent on the breakpoints used, the aim of the study was to compare the antimicrobial susceptibility results to different classes of antibiotics of 512 strains of Enterobacteriaceae (200 ESβL positive) isolated from bloodstream using CLSI 2013 and current EUCAST 2013 guidelines to evaluate the impact of break-point discrepancies. The results of the study showed that statistically significant discrepancies (p ≤ 0.001) were found for amoxicillin/clavulanic acid, piperacillin alone or with tazobac-tam, imipenem, meropenem, cefepime (only ESβL negative isolates), amikacin and gentamicin using current CLSI or EUCAST interpretive criteria. Further harmonization of CLSI and EUCAST breakpoints is warranted. This study could give useful information to physicians for managing bloodstream infections caused by Enterobacteriaceae.

KEYWORDS


Cite this paper

Blandino, G. , Mastrojeni, S. , Inturri, R. , Sciacca, A. and Nicoletti, G. (2014) Antimicrobial susceptibility of strains of Enterobacteriaceae isolated from bloodstream infections using current CLSI and EUCAST breakpoints. Health, 6, 153-157. doi: 10.4236/health.2014.62024.

References

[1] Tumbarello, M., Sanguinetti, M., Montuori, E., Trecarichi, E.M., Posteraro, B., Fiori, B., Citton, R., D’Inzeo, T., Fadda, G., Cauda, R. and Spanu, T. (2007) Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Entero-bacteriaceae: Importance of inadequate initial antimicrobial treatment. Antimicrobial Agents and Chemotherapy, 51, 1987-1994.
http://dx.doi.org/10.1128/AAC.01509-06
[2] Blandino, G., Nicoletti, G. and Nicolosi, D. (2011) Susceptibility of molecularly characterized hospital-associated methicillin-resistant Staphylococcus aureus isolates to dalbavancin. Journal of Chemotherapy, 23, 306-307.
[3] Chazan, B., Raz R., Teitler, N., Nitzan, O., Edelstein, H. and Colodner, R. (2009) Epidemiology and susceptibility to antimicrobials in community, hospital and long-term care facility bacteremia in northern Israel: A 6 year surveillance. Israel Medical Association Journal, 11, 592-597.
[4] Kallen, A.J., Hidron, A.I., Patel, J. and Srinivasan, A. (2010) Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008. Infection Control and Hospital Epidemiology, 31, 528-531. http://dx.doi.org/10.1086/652152
[5] Moehario, L.H., Tjoa, E., Kiranasari, A., Ningsih, I., Rosana, Y. and Karuniawati, A. (2009) Trends in antimicrobial susceptibility of gram-negative bacteria isolated from blood in Jakarta from 2002 to 2008. Journal of Infection in Developing Countries, 3, 843-848.
[6] Nicolosi, D., Nicolosi, V.M., Cappellani, A., Nicoletti, G. and Blandino, G. (2009) Antibiotic susceptibility profiles of uncommon bacterial species causing severe infections in Italy. Journal of Chemotherapy, 21, 253-260.
[7] European Centre for Disease Prevention and Control (ECDC) (2012) Antimicrobial resistance surveillance in Europe 2011. Surveillance Report.
www.ecdc.europa.eu
[8] The European Committee on Antimicrobial Susceptibility testing (2010) Breakpoint tables for interpretation of MICs and zone diameters. Version 1.1, EUCAST.
http://www.eucast.org/antimicrobial_susceptibility_testing/previous_versions_of_tables/
[9] Clinical and Laboratory Standards Institute (2010) Performance standards for antimicrobial susceptibility testing. 20th Informational Supplement Document M100-S20, CLSI, Wayne.
[10] Hombach, M., Wolfensberg, A., Kuster, S.P. and Böttger, E.C. (2013) Influence of clinical breakpoint changes from CLSI 2009 to EUCAST 2011 antimicrobial susceptibility testing guidelines on multidrug resistance rates of Gram-negative rods. Journal of Clinical Microbiology, 51, 2385-2387. http://dx.doi.org/10.1128/JCM.00921-13
[11] Van der Bij, A.K., Van Dijk, K., Muilwijk, J., Thijsen, S.F., Notermans, D.W., De Greeff, S. and Van de Sande-Bruinsma, N. (2012) ISIS-AR study group. Clinical breakpoint changes and their impact on surveillance of antimicrobial resistance in Escherichia coli causing bacteraemia. Clinical Microbiology and Infection, 18, E466-E472.
http://dx.doi.org/10.1111/j.1469-0691.2012.03996.x
[12] Clinical and Laboratory Standards Institute (2013) Performance standards for antimicrobial susceptibility testing. 23rd Informational Supplement Document M100-S23, CLSI, Wayne.
[13] The European Committee on Antimicrobial Susceptibility testing (2013) Breakpoint tables for interpretation of MICs and zone diameters. Version 3.1, EUCAST.
http://www.eucast.org/antimicrobial_susceptibility_testing/previous_versions_of_tables/
[14] Nordmann, P., Picazo, J.J., Mutters, R., Korten, V., Quintana, A., Laeuffer, J.M., Seak, J.C., Flamm, R.K. and Morrissey, I. (2011) on behalf of the COMPACT study group. Comparative activity of carbapenem testing: The COMPACT study. Journal of Antimicrobial Chemotherapy, 66, 1070-1078. http://dx.doi.org/10.1093/jac/dkr056
[15] Schito, G.C., Gualco, L., Naber, K.G., Botto, H., Palou, J., Mazzei, T. and Marchese, A. (2010) Do different susceptibility breakpoints affect the selection of antimicrobials for treatment of uncomplicated cystitis? Journal of Chemotherapy, 22, 345-354.
[16] Hombach, M., Muottet, B. and Bloemberg, G.V. (2013) Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESβL-and AmpC β-lactamase-producing clinical Enterobacteriaceae isolates. Journal of Antimicrobial Chemotherapy, 68, 2092-2098.
[17] Hawser, S.P., Badal, R.E., Bouchillon, S.K., Hoban, D.J. and Hsueh, P.R. (2010) Comparison of CLSI 2009, CLSI 2010 and EUCAST cephalosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiellap-neumoniae and Klebsiellaoxytoca from the SMART Global Surveillance Study. International Journal of Antimicrobial Agents, 36, 293-294.
http://dx.doi.org/10.1016/j.ijantimicag.2010.05.012
[18] Kristo, I., Pitiriga, V., Poulou, A., Zarkotou, O., Kimouli, M., Pournaras, S. and Tsakris, A. (2013) Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum β-lactamases using the update Clinical and Laboratory Standards Institute interpretative criteria. International Journal of Antimicrobial Agents, 41, 383-387.
http://dx.doi.org/10.1016/j.ijantimicag.2012.12.003
[19] Rodriguez-Baño, J., Picó, E., Navarro, M.D., López-Cerero, L., Pascual á. and the ESBL-REIPI Group (2012) Impact of changes in CLSI and EUCAST breakpoints for susceptibility in bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli. Clinical Microbiology and Infection, 18, 894-900.
http://dx.doi.org/10.1111/j.1469-0691.2011.03673.x

comments powered by Disqus

Copyright © 2014 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.